Literature DB >> 2546780

Increased cyclic AMP levels block interleukin 2-induced protein kinase C substrate phosphorylation but not the mitogenic response.

B Friedrich1, D A Cantrell, M Gullberg.   

Abstract

Protein kinase C (PKC) has been implicated in the signaling of a number of cellular responses including activation of T cells. In the present report we have evaluated the effect of increased cAMP levels on PKC activation after stimulation of two distinct receptor systems on normal human T cells. PKC substrate phosphorylation can be induced via either the CD3 complex or, to a limited extent, the high affinity interleukin 2 (IL 2) receptor. Substrate phosphorylation via both pathways is shown to be blocked by increased intracellular levels of cAMP. In accordance with previous reports, the CD3-dependent autocrine proliferative response could also be blocked by a cAMP-dependent mechanism. Since direct activation of PKC with a phorbol ester reversed this inhibition, a causal relationship between cAMP-dependent PKC blockage and inhibition of the CD3 response is suggested. In contrast, however, initiation of IL 2-induced proliferation was essentially unaltered by cAMP and could progress in the apparent absence of PKC activity. Thus, this study indicates that IL 2-induced proliferation can under such conditions be completely uncoupled from IL 2-induced PKC activation in normal T cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2546780     DOI: 10.1002/eji.1830190622

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  2 in total

1.  Regulation of IL-4 lymphokine gene expression and cellular proliferation in murine T helper type II cells.

Authors:  E Muñoz; A M Zubiaga; J Muñoz; B T Huber
Journal:  Cell Regul       Date:  1990-04

2.  Nitric oxide production in murine spleen cells: role of interferons and prostaglandin E(2) in the generation of cytotoxic activity.

Authors:  D Vaillier; R Daculsi; N Gualdel
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.